Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial

Similar Items

• Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
  od: Li, Tianhong, i dr.
  Izdano: (2016)
• Lung cancer in never smokers—the East Asian experience
  od: Zhou, Fei, i dr.
  Izdano: (2018)
• Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
  od: Yang, James Chin-Hsin, i dr.
  Izdano: (2015)
• Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
  od: Li, Chenguang, i dr.
  Izdano: (2011)
• A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
  od: Wang, Siying, i dr.
  Izdano: (2013)